论文部分内容阅读
足量的联合化疗治疗急件髓性白血病（ＡＮＬＬ）现已疗效肯定。然而，对一部分强化疗不能耐受的ＡＮＬＬ，如何进行治疗，仍是当前极需解决的难题之一。我院１９９５年以来，采用依托泊甙（ＶＰ１６胶囊）为主，联合ＬＤ－ＨＡ方案组成ＬＤ－ＥＨＡ方案治疗强化疗不能耐受的Ａ
A sufficient amount of combined chemotherapy for acute myeloid leukemia (ANLL) has now been confirmed. However, how to treat ANLL that can not be tolerated by a part of strong chemotherapy is still one of the most difficult problems to be solved. Since 1995 in our hospital, Etoposide (VP16 capsules) has been used as the main method, and LD-HA regimen has been combined with LD-EHA regimen to treat A that can not be tolerated by chemotherapy.